Buxton MJ, Drummond MF, van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217–27
PubMed
Article
CAS
Google Scholar
Eddy DM. Technology assessment: the role of mathematical modelling. In: Mosteller F, editor. Assessing medical technologies. Washington, DC: National Academy Press, 1985: 144–53
Google Scholar
Michaels JA, Galland RB. Management of asymptomatic popliteal aneurysms: the use of a Markov decision tree to determine the criteria for a conservative approach. Eur J Vasc Surg 1993; 7 (2): 136–43
PubMed
Article
CAS
Google Scholar
Barnhart HX, Caldwell MB, Thomas P, et al. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics 1996; 97 (5): 710–6
PubMed
CAS
Google Scholar
Ludbrook A. A cost—effectiveness analysis of the treatment of chronic renal failure. Appl Econ 1981; 13: 337–50
Article
Google Scholar
Hillner BE, Mc Leod DG, Crawford ED, et al. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology 1995; 45 (5): 633–40
PubMed
Article
CAS
Google Scholar
Sculpher M, Michaels J, Mc Kenna M, et al. A cost—utility analysis of laser—assisted angioplasty for peripheral arterial occlusions. Int J Technol Assess Health Care 1996; 12 (1): 104–25
PubMed
Article
CAS
Google Scholar
Briggs AH, Sculpher MJ, Logan RP, et al. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. BMJ. 1996; 312 (7042): 1321–5
PubMed
Article
CAS
Google Scholar
Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322–38
PubMed
Article
CAS
Google Scholar
Bloom BS, Fendrick AM. Timing and timeliness in medicalcare evaluation. Pharmacoeconomics 1996; 9 (3): 183–7
PubMed
Article
CAS
Google Scholar
Sculpher MJ, Drummond MF, Buxton MJ. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 1997; 2: 26–30
PubMed
CAS
Google Scholar
Clemens K, Garrison LP, Jones A, et al. Strategic use of pharmacoeconomic research in early drug development and global pricing. Pharmacoeconomics 1993; 4 (5): 315–22
PubMed
Article
CAS
Google Scholar
Torgerson D, Donaldson C, Reid D. Using economics to prioritize research: a case study of randomized trials for the prevention of hip fractures due to osteoporosis. J Health Serv Res Policy 1996; 1: 141–6
PubMed
CAS
Google Scholar
Townsend J, Buxton M. Cost—effectiveness scenario analysis for a proposed trial of hormone replacement therapy. Health Policy 1997; 39: 181–94
PubMed
Article
CAS
Google Scholar
Glick H, Heyse JF, Thompson D, et al. A model for evaluating the cost—effectiveness of cholesterol—lowering treatment. Int J Technol Assess Health Care 1992; 8 (4): 719–34
PubMed
Article
CAS
Google Scholar
Shepherd J, Cobbe SM, Ford I, West of Scotland Coronary Prevention Study Group, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333 (20): 1301–7
PubMed
Article
CAS
Google Scholar
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344 (8934): 1383–9
Google Scholar
Johannesson M, Jonsson B, Kjekshus J, Scandinavian Simvastatin Survival Study Group, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336 (5): 332–6
PubMed
Article
CAS
Google Scholar
Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332 (21): 1418–24
PubMed
Article
CAS
Google Scholar
Bryan S, Brown J. Extrapolation of cost—effectiveness information to local settings. Brunel: Brunel University, 1997. Health Economics Research Group (HERG) discussion paper no.: 17
Google Scholar
Gompertz B. On the nature of the of the function expressive of the law of human mortality. Phil Trans R Soc Lond 1825; 115: 513–85
Article
Google Scholar
Neilson S, Robinson I, Hunter M. Static and dynamic models of interdisease competition: past and projected mortality from amyotrophic lateral sclerosis and multiple sclerosis. Mech Ageing Dev 1993; 66: 223–41
PubMed
Article
CAS
Google Scholar
Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994; 14: 52–8
PubMed
Article
CAS
Google Scholar
Johannesson M. On the discounting of gained life—years in costeffectiveness analysis. Int J Technol Assess Health Care 1992; 8 (2): 359–64
PubMed
Article
CAS
Google Scholar
Parsonage M, Neuburger H. Discounting and health benefits. Health Econ 1992; 1 (1): 71–6
PubMed
Article
CAS
Google Scholar
Cairns J. Discounting and health benefits: another perspective. Health Econ 1992; 1 (1): 76–9
PubMed
Article
CAS
Google Scholar
Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312 (7040): 1215–8
PubMed
Article
CAS
Google Scholar